Today's Quote

Don't listen to the person who has the answers;
listen to the person who has the questions.
Albert Einstein

An inexpensive drug may be used to counteract treatment resistance in acute myeloid leukemia

Nikolas Herold, assistant professor at the Department of Women’s and Children’s Health. Photo: Karolinska Universitetssjukhuset.

Article Highlights

A common and inexpensive drug may be used to counteract treatment resistance in patients with acute myeloid leukemia (AML), one of the most common forms of blood cancer. The researchers will now launch a clinical study to test the new combination treatment in patients.
Leukemia is a group of blood cancers that results in excess amounts of white blood cells. There are both chronic forms of leukemia that progress slowly over many years and acute types of leukemia that evolve rapidly. AML affects more than 20,000 people in the United States each year, and the mortality rate is high especially in older patients.
One of the most common drugs to treat AML is cytarabine (ara-C), a cytotoxic drug that interferes with DNA replication. However, many patients do not respond to the treatment because their leukemic cells express high levels of the enzyme SAMHD1, which breaks down the active metabolite of cytarabine, ara-CTP. These patients have a significantly worse survival rate than patients with low leukemic levels of SAMHD1. Therefore, one promising strategy to improve the treatment of AML is to inhibit the effects of this enzyme on cytarabine.
In this study, the researchers tested the impact of more than 33,000 different substances on SAMHD1’s ability to break down ara-CTP in leukemia cells treated with cytarabine. The experiment led to the identification of three different substances, so-called ribonucleotide reductase inhibitors (RNRi), that all reduced SAMHD1’s ability to deactivate ara-CTP: hydroxyurea, gemcitabine and triapine.
“Adding any of these three substances significantly improved the effect of the cytarabine-treatment in cell samples with high levels of SAMHD1,” says Nikolas Herold, researcher at the Department of Women’s and Children’s Health at Karolinska Institutet in Sweden. “This was true for AML samples from both adults and children. In AML-mice, we also saw that the median survival was significantly prolonged when cytarabine was combined with an RNR-inhibitor.”
Hydroxyurea is an inexpensive drug that is used to treat blood diseases such as AML. However, it has not systematically been used in combination with cytarabine. Gemcitabine is a potent drug that is used to treat many different types of cancers, but it can be toxic if given repeatedly. Triapine is a drug currently undergoing clinical studies for cancer treatment. In animal studies, the combination therapies did not exhibit any excess side-effects beyond those already established in cytarabine-treatments.
The research group is now planning to move forward with a clinical study that will evaluate the effect of combining standard AML-treatment with hydroxyurea in recently diagnosed patients. The study will be conducted in collaboration with the Swedish AML-group and will begin recruiting patients within a few weeks.

The Complete Story: Cheap drug may alleviate treatment-resistance in leukemia

Karolinska Institutet

Go deeper with Bing News on:

Acute myeloid leukemia

Apollomics Announces Completion of Business Combination and Listing on Nasdaq
By using targeted therapy, immuno-oncology agents, and other innovative approaches, Apollomics' novel drug candidates have the potential to address a range of cancers, including lung cancer, brain ...
Discovery could be key to reducing leukemia treatment resistance
In a world first, Newcastle researchers have discovered the mechanisms acute myeloid leukemia (AML) cells use to produce "free radicals"—the byproduct of a cell process that aggressively fuels the ...
What Is Leukemia?
Leukemia is a form of blood cancer that starts in your bone marrow, the spongy tissue inside your bones. It occurs when abnormal cells grow too fast and survive too long. Over time, the abnormal cells ...
OncoVerity eyes cusatuzumab development in AML after licensing rights
OncoVerity announced the acquisition of worldwide licensing rights of the anti-CD70 monoclonal antibody cusatuzumab from the biotech argenx. Alongside this, the company closed a $30 million Series A, ...
Relapsed Acute Myeloid Leukemia Drug Market Increasing Growth and End Users in Forthcoming Years by 2023-2030
The Relapsed Acute Myeloid Leukemia Drug Market (2023-2030) Updated Latest Research Report analyzes the market's ...

Go deeper with Google Headlines on:

Acute myeloid leukemia

[google_news title=”” keyword=”acute myeloid leukemia” num_posts=”5″ blurb_length=”0″ show_thumb=”left”]

Go deeper with Bing News on:

AML

iDenfy’s New Partnership with Fincapital Partners: Increased Security Through KYC/AML Tools
Denfy, a Lithuania-based RegTech offering ID verification and fraud prevention tools, announced joining forces with Fincapital Partners, a fintech offering a suite of tools from trading and crypto ...
William Hill fined record $23.7M for social responsibility, AML failures
The U.K. Gambling Commission announced three units of British bookmaking service William Hill Group will pay a record fine of £19.2 million (U.S. $23.7 million) for failures regarding social ...
EU politicians back plan for new AML authority
On March 29, members of the European Parliament voted on draft anti-money laundering and countering the financing of terrorism (AML/CFT) legislation, including plans for a new AML watchdog. Key ...
Ebrd, Acams Launch Training On Aml in Tunisia and Other Mediterranean Countries
Two scholarship programmes to provide anti-money laundering (AML) and sanctions compliance training to 120 anti-financial crime (AFC) professionals throughout the southern and eastern Mediterranean ...
CipherTrace Publishes AML, Crypto Crime Report
CipherTrace, acquired by Mastercard (NYSE: MA) in 2021, has posted a report on money laundering and crypto crime.

Go deeper with Google Headlines on:

AML

[google_news title=”” keyword=”AML” num_posts=”5″ blurb_length=”0″ show_thumb=”left”]

Tags: Acute myeloid leukemia AML karolinska institutet

Related Articles

Leave a Reply

This site uses Akismet to reduce spam. Learn how your comment data is processed.

Copyright 2023. Created by Innovation Toronto

Desktop Version Mobile Version